Wegovy’s early lead to narrow as Eli Lilly prepares Foundayo launch

Eli Lilly's (NYSE: LLY) new oral obesity pill is expected to surpass Novo Nordisk's in the long-term, despite near-term dominance. Lilly's Q1 earnings are forecasted to be strong, driven primarily by its obesity and diabetes franchises.